Garlipp B, Gibbs P, Van Hazel GA, et al. - Researchers examined how technical resectability of colorectal cancer liver metastases (CRLM) has changed with the addition of selective internal radiotherapy (SIRT) to FOLFOX-based chemotherapy. Three or five (of 14) expert hepatopancreatobiliary surgeons reviewed baseline and follow-up hepatic imaging of patients who received modified FOLFOX (mFOLFOX6: fluorouracil, leucovorin, oxaliplatin) chemotherapy with or without bevacizumab (control arm) vs mFOLFOX6 (with or without bevacizumab) plus SIRT using yttrium-90 resin microspheres (SIRT arm) in the phase III SIRFLOX trial, for resectability. They identified some 472 patients as evaluable. At follow-up, significantly more patients in both arms vs baseline were deemed technically resectable. The SIRT arm had more patients who were resectable relative to the control arm: 93 of 244 (38·1%) vs 66 of 228 (28·9%) respectively. Outcomes thereby suggest the possibility of improving the resectability of unresectable CRLM with the addition of SIRT to chemotherapy.